reanalysis of medical therapies in order to reveal concealed risks often covered by good intentions. Through a joint obstetrical and perinatal effort, further quality studies involving large sample populations may help further clarify the etiology of the association of high-dosage MgSO 4 with adverse neonatal outcomes. To prevent continued serious neonatal morbidity and mortality, judicious avoidance of high-dose MgSO 4 for preterm labor tocolysis is warranted.
Reply to Dr McAdam's letter: pulmonary interstitial emphysema, antenatal magnesium sulfate and mortality in the extremely low birth weight infants We thank Dr McAdams for his letter and appreciate his comments.
We found an association between Mg10 and pulmonary interstitial emphysema (PIE) and between PIE and death in the extremely low birth weight (ELBW) infants in our study. 1 However, it was not clear if death was due to these two adverse factors individually, or a combination of both. We compared infants who received Mg10 with those who did not receive Mg10 for clinical course and outcome variables. Mg10 infants had lower gestational age (GA, 25.3±1.2 vs 26.6±1.5 weeks, P ¼ 0.08); higher incidence of PIE (47 vs 18%, P ¼ 0.05); and greater incidence of death (31 vs 7%, P ¼ 0.03). Total number of days on high frequency oscillatory ventilator (HFOV, 5.2±6 vs 0.5±1.1 days, P ¼ 0.01) and the cumulative magnesium sulfate (MgSO 4 ) dose (43±23 vs 2±3.7 g, P<0.001) were also higher in the Mg10 group. The mode of delivery, duration of rupture of the membranes, use of pressers, culture proven sepsis, days on antibiotics or incidence of placental chorioamnionitis did not differ between the two groups. In a multiple logistic regression analysis, using a model which included Mg10, PIE, GA, HFOV days and MgSO 4 dose only PIE remained significantly associated with death (Odd's ratio 14.4, 95% CI 1-208, P ¼ 0.05) after controlling for all other significant predictors, suggesting that death due to Mg10 is dependent upon the development of PIE in ELBW infants. MgSO 4 tocolysis has been associated with neonatal death in prior studies 2 but only one study has demonstrated a dose relationship between the two variables and established an antenatal dose >48 g of MgSO 4 to be associated with death. 3 Our mean cumulative dose was lesser than this amount which might also explain the lack of association between Mg10 and death in the multivariate analysis.
Both pregnancy induced hypertension (PIH) and antenatal steroid administration (ANS) in mothers are considered to be redeeming factors for death and severity of pulmonary disease. As there were only 11 patients in the PIE group, the analysis would not have been powerful enough to yield any worthwhile results if these infants were further subgrouped for examining outcomes related with MgSO 4 given for tocolysis or for PIH; and compared with the no-PIE group. However, we compared infants who received antenatal MgSO 4 for PIH (n ¼ 9) with those who received the drug for tocolysis only (n ¼ 22) in the absence of PIH in the entire cohort. All infants in the non-PIH group received surfactant compared to 62% in PIH group (P ¼ 0.01), 55% developed PIE (vs 25%, P ¼ 0.1), 60 % had chorioamnionitis (vs 12.5%, P ¼ 0.02) and 30% died as opposed to none (P ¼ 0.08). As the dose of MgSO 4 (mean 31 vs 34 g) or PIE did not differ, an increased occurrence of both RDS and death in the non-PIH group could possibly be attributed to the effects of PIH. The higher incidence of chorioamnionitis in the non-PIH group needs further evaluation. All these analyses should be taken with some reservation due to a low number of observations. ANS was not compared between the groups, again due to a lack of power.
Out of the two infants who died but did not suffer from PIE, one did not receive MgSO 4 and the other one was exposed to a cumulative dose of 44 g. The serum levels of magnesium and the radiological classification of PIE were not taken into account for the purpose of this study. However, we noticed a trend towards early occurrence of PIE in the Mg10 infants, being as early as on day of life 0 or the first radiological study. A total of eight out of 11 infants with PIE (72%) were treated with HFOV as opposed to only two in the 34 no-PIE group (5.8%).
PIE and antenatal MgSO 4 appear to be significant risk factors for mortality, as well as adverse neurological sequale in ELBW infants. 1, 4 The American Academy of Pediatrics in 2002 issued a statement emphasizing that the future investigations in infants at the threshold of viability should be directed at neurodevelopmental outcome and survival as primary study outcomes, underscoring the significance of these two variables. 5 It is possible that decreasing the incidence of PIE by understanding its pathogenesis, prevention and management better, as well as judicious use of MgSO 4 would further help in achieving these important goals in the ELBW infants.
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